CRISIL Profit Jumps 46% on Strong Performance, Stock Rises

CRISIL's strong results show a key shift in how it operates. The company is moving beyond just increasing revenue to improving its efficiency and pricing. Better EBITDA margins indicate that managing costs and optimizing service delivery are now major factors in its profitability, a development investors are watching closely.

Margin Growth Fuels Profit Surge

CRISIL's latest quarterly results showcase a powerful mix of accelerated revenue growth and improved margin expansion. Net profit jumped 46% year-on-year to Rs 233.3 crore, a significant increase from Rs 160 crore a year ago. This profit growth was supported by a 30% rise in revenue from operations, reaching Rs 1,058 crore compared to Rs 813.2 crore previously. The most notable aspect is the improvement in EBITDA margins, which widened to 30.1% from 28.5% a year earlier. This 1.6 percentage point increase in margin points to enhanced operational efficiencies and effective cost controls. The stock reacted positively, rising over 6% and reaching an intra-day high of Rs 4,383 on the National Stock Exchange, marking its third consecutive session of gains. An interim dividend of Rs 9 per share was also announced, further boosting investor confidence.

Market Position and Financial Strength

CRISIL holds a dominant position in India's credit rating and analytics sector, with over 60% market share. It consistently shows faster revenue growth than peers like CARE Ratings and ICRA, with a 12.6% compound annual growth rate (CAGR) over five years, versus 6.4% for CARE and 6.8% for ICRA. Its Return on Equity (ROE) has averaged a strong 30.5% over a five-year period, far exceeding CARE's 14.3% and ICRA's 13.7%. Some peer comparisons based on older data from October 2024 showed CRISIL's P/E ratio around 52.9x, higher than CARE's 34.8x and ICRA's 45.3x. Current market data as of April 2026 places CRISIL's P/E in the 39-49x range. This suggests investors value CRISIL's market leadership and steady growth. India's financial services sector is expected to grow strongly, though it faces challenges like inflation and global uncertainties. CRISIL's focus on analytics and risk solutions places it well to benefit from this expansion.

Risks and Challenges

Despite strong earnings, potential challenges remain. CRISIL's P/E ratio has often traded at a premium to peers. Figures around 39-49x as of April 2026 could be seen as high, especially compared to CARE Ratings' P/E of 11.5x in a prior analysis. While CRISIL leads in revenue growth and ROE, its EBITDA and net profit margins have historically been lower than ICRA and CARE Ratings in absolute terms. The company also has contingent liabilities totaling Rs 741.84 crore that need attention. The stock has experienced recent weakness, trading down -2.49% over the past year as of April 11, 2026, suggesting broader market sentiment has impacted its performance despite positive earnings reports. Additionally, increasing competition in analytics, advisory, and ESG ratings could threaten its market share and future growth.

Analyst Views and Future Growth

Analysts generally recommend buying CRISIL, with most holding a positive outlook. The average 12-month price target is between Rs 4,632 and Rs 4,904, indicating a potential 12-20% upside from current levels. Revenue growth is expected to continue, with a projected CAGR of 13% over the next three years. Management is focused on expanding its global analytics and solutions businesses, expecting continued growth fueled by India's projected GDP expansion of 7.4% in FY25-26.